Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $274.2 million.

  • Regenxbio's Cash & Current Investments rose 733.77% to $274.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.2 million, marking a year-over-year increase of 733.77%. This contributed to the annual value of $234.7 million for FY2024, which is 1473.93% down from last year.
  • Regenxbio's Cash & Current Investments amounted to $274.2 million in Q3 2025, which was up 733.77% from $323.3 million recorded in Q2 2025.
  • Regenxbio's Cash & Current Investments' 5-year high stood at $457.4 million during Q4 2021, with a 5-year trough of $234.7 million in Q4 2024.
  • Over the past 5 years, Regenxbio's median Cash & Current Investments value was $331.8 million (recorded in 2023), while the average stood at $335.3 million.
  • Per our database at Business Quant, Regenxbio's Cash & Current Investments skyrocketed by 5787.61% in 2021 and then crashed by 2451.28% in 2023.
  • Regenxbio's Cash & Current Investments (Quarter) stood at $457.4 million in 2021, then dropped by 20.29% to $364.6 million in 2022, then fell by 24.51% to $275.3 million in 2023, then decreased by 14.74% to $234.7 million in 2024, then increased by 16.84% to $274.2 million in 2025.
  • Its last three reported values are $274.2 million in Q3 2025, $323.3 million for Q2 2025, and $267.9 million during Q1 2025.